8-K Announcements
6Material company update
Mar 18, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Feb 12, 2026·SEC
Arvinas, Inc.(ARVN)Earnings, Financials & Key Ratios
ARVN•NASDAQ
$10.61
$679M mkt cap·Price updated May 6, 2026
AboutArvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.Show more
- Revenue$263M-0.3%
- EBITDA-$110M+55.0%
- Net Income-$81M+59.4%
- EPS (Diluted)-1.28+53.8%
- Gross Margin98.02%-2.0%
- EBITDA Margin-41.77%+54.8%
- Operating Margin-43.75%+53.9%
- Net Margin-30.77%+59.3%
- ROE-16.23%+50.2%
- ROIC-22.37%+51.0%
- Debt/Equity0.02+13.4%
ARVN Key Insights
Arvinas, Inc. (ARVN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 58.9%
- ✓Share count reduced 9.7% through buybacks
✗Weaknesses
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ARVN Price & Volume
Arvinas, Inc. (ARVN) stock price & volume — 10-year historical chart
Loading chart...
ARVN Growth Metrics
Arvinas, Inc. (ARVN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years58.93%
3 Years25.96%
TTM-0.3%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM59.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM55.96%
Return on Capital
10 Years-33.51%
5 Years-24.77%
3 Years-27.31%
Last Year-15.99%
ARVN Recent Earnings
Arvinas, Inc. (ARVN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 7/12 qtrs (58%)
Q1 2026Latest
Feb 24, 2026EPS
$1.10
Est $0.55
-100.0%
Revenue
$10M
Est $37M
-74.5%
Q4 2025
Nov 5, 2025EPS
$0.48
Est $0.75
+36.0%
Revenue
$42M
Est $37M
+12.4%
Q3 2025
Aug 6, 2025EPS
$0.84
Est $0.87
+3.4%
Revenue
$22M
Est $25M
-10.4%
Q2 2025
May 1, 2025EPS
$1.14
Est $0.86
+232.6%
Revenue
$189M
Est $42M
+346.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 24, 2026 | $1.10vs $0.55-100.0% | $10Mvs $37M-74.5% |
| Q4 2025 | Nov 5, 2025 | $0.48vs $0.75+36.0% | $42Mvs $37M+12.4% |
| Q3 2025 | Aug 6, 2025 | $0.84vs $0.87+3.4% | $22Mvs $25M-10.4% |
| Q2 2025 | May 1, 2025 | $1.14vs $0.86+232.6% | $189Mvs $42M+346.3% |
Based on last 12 quarters of dataView full earnings history →
ARVN Peer Comparison
Arvinas, Inc. (ARVN) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 6.75B | 82.71 | -22.41 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 | ||
 MDGL | 11.41B | 502.47 | -39.10 | 432.05% | -39.04% | -46.21% | 0.00 | |
 PTCT | 5.39B | 65.04 | 8.36 | 114.51% | 39.44% | 13.02% | ||
 RCUS | 2.62B | 26.06 | -7.92 | -4.26% | -156.36% | -68.97% | 0.16 | |
 RVMD | 29B | 147.21 | -24.74 | -69.35% | 0.10 | |||
 PFE | 150.4B | 26.44 | 19.44 | -1.65% | 11.83% | 8.34% | 6.03% | 0.78 |
 BMY | 116.22B | 56.92 | 16.50 | -0.22% | 15.01% | 38.96% | 11.05% | 2.55 |
Compare ARVN vs Peers
Arvinas, Inc. (ARVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARVN Income Statement
Arvinas, Inc. (ARVN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 7.58M | 14.32M | 42.98M | 25.9M | 53.6M | 131.4M | 78.5M | 263.4M | 262.6M |
| Revenue Growth % | 13.64% | 89% | 200.03% | -39.73% | 106.95% | 145.15% | -40.26% | 235.54% | -0.3% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.2M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 1.98% |
| Gross Profit | 7.58M▲ 0% | 14.32M▲ 89.0% | 42.98M▲ 200.0% | 25.9M▼ 39.7% | 53.6M▲ 106.9% | 131.4M▲ 145.1% | 78.5M▼ 40.3% | 263.4M▲ 235.5% | 257.4M▼ 2.3% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 98.02% |
| Gross Profit Growth % | 13.64% | 89% | 200.03% | -39.73% | 106.95% | 145.15% | -40.26% | 235.54% | -2.28% |
| Operating Expenses | 32.34M | 58.13M | 94.5M | 146.7M | 242M | 394.6M | 480M | 513.6M | 372.3M |
| OpEx % of Revenue | 426.7% | 405.8% | 219.89% | 566.41% | 451.49% | 300.3% | 611.47% | 194.99% | 141.77% |
| Selling, General & Admin | 3.55M | 12.93M | 27.31M | 38.3M | 61.6M | 79.6M | 100.3M | 165.4M | 89.4M |
| SG&A % of Revenue | 46.79% | 90.28% | 63.54% | 147.88% | 114.93% | 60.58% | 127.77% | 62.79% | 34.04% |
| Research & Development | 28.79M | 45.19M | 67.19M | 108.4M | 180.4M | 315M | 379.7M | 348.2M | 282.9M |
| R&D % of Revenue | 379.91% | 315.51% | 156.35% | 418.53% | 336.57% | 239.73% | 483.69% | 132.19% | 107.73% |
| Other Operating Expenses | 0 | 102.73K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24.76M▲ 0% | -43.8M▼ 76.9% | -51.52M▼ 17.6% | -120.8M▼ 134.5% | -188.4M▼ 56.0% | -263.2M▼ 39.7% | -401.5M▼ 52.5% | -250.2M▲ 37.7% | -114.9M▲ 54.1% |
| Operating Margin % | -326.7% | -305.8% | -119.89% | -466.41% | -351.49% | -200.3% | -511.47% | -94.99% | -43.75% |
| Operating Income Growth % | -50.34% | -76.9% | -17.63% | -134.45% | -55.96% | -39.7% | -52.55% | 37.68% | 54.08% |
| EBITDA | -24.41M | -43.1M | -49.27M | -117.6M | -182.4M | -255M | -394.8M | -243.6M | -109.7M |
| EBITDA Margin % | -322.12% | -300.87% | -114.65% | -454.05% | -340.3% | -194.06% | -502.93% | -92.48% | -41.77% |
| EBITDA Growth % | -52.27% | -76.53% | -14.33% | -138.68% | -55.1% | -39.8% | -54.82% | 38.3% | 54.97% |
| D&A (Non-Cash Add-back) | 347.39K | 706K | 2.25M | 3.2M | 6M | 8.2M | 6.7M | 6.6M | 5.2M |
| EBIT | -24M | -41.42M | -70.21M | -120.8M | -188.4M | -263.2M | -401.5M | -250.2M | -80.5M |
| Net Interest Income | 151.03K | 2.41M | 4.5M | 3.52M | 1.7M | 12M | 38.8M | 54.8M | 22M |
| Interest Income | 201.39K | 2.47M | 4.6M | 3.59M | 1.8M | 12M | 38.8M | 54.8M | 22M |
| Interest Expense | 50.36K | 57.44K | 100K | 65K | 100K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 711.06K | 2.32M | -18.79M | 1.5M | -2.6M | 1.6M | 35.1M | 51.9M | 34.4M |
| Pretax Income | -24.05M▲ 0% | -41.48M▼ 72.5% | -70.3M▼ 69.5% | -119.3M▼ 69.7% | -191M▼ 60.1% | -261.6M▼ 37.0% | -366.4M▼ 40.1% | -198.3M▲ 45.9% | -80.5M▲ 59.4% |
| Pretax Margin % | -317.32% | -289.59% | -163.58% | -460.62% | -356.34% | -199.09% | -466.75% | -75.28% | -30.65% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 20.9M | 900K | 600K | 300K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -7.99% | -0.25% | -0.3% | -0.37% |
| Net Income | -24.05M▲ 0% | -41.48M▼ 72.5% | -70.29M▼ 69.5% | -119.3M▼ 69.7% | -191M▼ 60.1% | -282.5M▼ 47.9% | -367.3M▼ 30.0% | -198.9M▲ 45.8% | -80.8M▲ 59.4% |
| Net Margin % | -317.32% | -289.59% | -163.56% | -460.62% | -356.34% | -214.99% | -467.9% | -75.51% | -30.77% |
| Net Income Growth % | -67.58% | -72.48% | -69.46% | -69.72% | -60.1% | -47.91% | -30.02% | 45.85% | 59.38% |
| Net Income (Continuing) | -24.05M | -41.48M | -70.3M | -119.3M | -191M | -282.5M | -367.3M | -198.9M | -80.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.38▲ 0% | -1.31▲ 5.1% | -1.89▼ 44.3% | -3.02▼ 59.8% | -3.82▼ 26.5% | -5.31▼ 39.0% | -6.62▼ 24.7% | -2.77▲ 58.2% | -1.28▲ 53.8% |
| EPS Growth % | 81.75% | 5.07% | -44.27% | -59.79% | -26.49% | -39.01% | -24.67% | 58.16% | 53.79% |
| EPS (Basic) | -1.38 | -1.31 | -1.89 | -3.02 | -3.82 | -5.31 | -6.62 | -2.77 | -1.28 |
| Diluted Shares Outstanding | 20.73M | 31.63M | 32.93M | 39.53M | 50M | 53.2M | 55.5M | 71.9M | 64.9M |
| Basic Shares Outstanding | 20.73M | 31.63M | 32.93M | 39.53M | 50M | 53.2M | 55.5M | 71.9M | 64.9M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ARVN Balance Sheet
Arvinas, Inc. (ARVN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 65.53M | 195.68M | 290.88M | 703.1M | 1.55B | 1.24B | 1.28B | 1.07B | 700.7M |
| Cash & Short-Term Investments | 39.17M | 187.83M | 280.87M | 688.6M | 1.5B | 1.21B | 1.26B | 1.04B | 685.4M |
| Cash Only | 30.91M | 3.19M | 9.21M | 588.4M | 108.3M | 81.3M | 311.7M | 100.5M | 142.9M |
| Short-Term Investments | 8.26M | 184.64M | 271.66M | 100.2M | 1.39B | 1.12B | 949.3M | 938.9M | 542.5M |
| Accounts Receivable | 26.04M | 5.03M | 6.28M | 8.4M | 25.7M | 8M | 7.2M | 13.7M | 6.4M |
| Days Sales Outstanding | 1.25K | 128.22 | 53.34 | 118.38 | 175.01 | 22.22 | 33.48 | 18.98 | 8.9 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 4.5M | 26.9M | 12M | 14.2M | 8.9M |
| Total Non-Current Assets | 1.32M | 3.6M | 10.76M | 14.3M | 29.1M | 28.6M | 24.4M | 24.1M | 17.2M |
| Property, Plant & Equipment | 1.3M | 3.58M | 10.73M | 14.3M | 16.6M | 17.8M | 14M | 16M | 13.4M |
| Fixed Asset Turnover | 5.83x | 4.00x | 4.00x | 1.81x | 3.23x | 7.38x | 5.61x | 16.46x | 19.60x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 20.76K | 20.76K | 26.76K | 0 | 12.5M | 10.8M | 10.4M | 8.1M | 3.8M |
| Total Assets | 66.85M▲ 0% | 199.28M▲ 198.1% | 301.64M▲ 51.4% | 717.4M▲ 137.8% | 1.58B▲ 120.5% | 1.27B▼ 19.8% | 1.3B▲ 2.8% | 1.09B▼ 16.3% | 717.9M▼ 34.2% |
| Asset Turnover | 0.11x | 0.07x | 0.14x | 0.04x | 0.03x | 0.10x | 0.06x | 0.24x | 0.37x |
| Asset Growth % | 76.21% | 198.11% | 51.36% | 137.83% | 120.46% | -19.78% | 2.82% | -16.34% | -34.22% |
| Total Current Liabilities | 17.85M | 22.98M | 32.81M | 49.2M | 261.7M | 295.1M | 257.1M | 229.8M | 142.5M |
| Accounts Payable | 596.53K | 2.76M | 4.56M | 7.1M | 31.3M | 5.7M | 17.8M | 13.4M | 24.2M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | 1.7K |
| Short-Term Debt | 159.26K | 154.46K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 13.55M | 16.07M | 19.98M | 22.2M | 206.2M | 218.6M | 163M | 156.2M | 71.3M |
| Other Current Liabilities | 0 | 0 | 5.81M | 9M | 12.4M | 18.7M | 48M | 0 | 40.5M |
| Current Ratio | 3.67x | 8.52x | 8.86x | 14.29x | 5.93x | 4.20x | 4.98x | 4.64x | 4.92x |
| Quick Ratio | 3.67x | 8.52x | 8.86x | 14.29x | 5.93x | 4.20x | 4.98x | 4.64x | 4.92x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 48.75M | 39.63M | 42.14M | 26M | 538.2M | 408.8M | 387.5M | 299.9M | 141.5M |
| Long-Term Debt | 151.12K | 2M | 2M | 2M | 1M | 1M | 800K | 600K | 400K |
| Capital Lease Obligations | 0 | 0 | 1.71M | 1.1M | 2.9M | 2.7M | 500K | 7.3M | 6.8M |
| Deferred Tax Liabilities | -61.43M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 50.89K | 150K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 66.6M | 62.61M | 74.96M | 75.2M | 799.9M | 703.9M | 644.6M | 529.7M | 284M |
| Total Debt | 310.39K | 2.15M | 4.39M | 4.1M | 5M | 5.5M | 3.2M | 9.7M | 8.5M |
| Net Debt | -30.6M | -1.04M | -4.82M | -584.3M | -103.3M | -75.8M | -308.5M | -90.8M | -134.4M |
| Debt / Equity | 1.26x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.00x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -476.57x | -721.15x | -702.07x | -1858.46x | -1884.00x | - | - | - | - |
| Total Equity | 245.87K▲ 0% | 136.67M▲ 55485.1% | 226.69M▲ 65.9% | 642.2M▲ 183.3% | 781.7M▲ 21.7% | 564.9M▼ 27.7% | 660M▲ 16.8% | 561.7M▼ 14.9% | 433.9M▼ 22.8% |
| Equity Growth % | -98.98% | 55485.06% | 65.87% | 183.3% | 21.72% | -27.73% | 16.83% | -14.89% | -22.75% |
| Book Value per Share | 0.01 | 4.32 | 6.88 | 16.24 | 15.63 | 10.62 | 11.89 | 7.81 | 6.69 |
| Total Shareholders' Equity | 245.87K | 136.67M | 226.69M | 642.2M | 781.7M | 564.9M | 660M | 561.7M | 433.9M |
| Common Stock | 1.19M | 31.24K | 38.46K | 0 | 0 | 100K | 100K | 100K | 100K |
| Retained Earnings | -62.42M | -302.26M | -372.56M | -491.9M | -682.9M | -965.4M | -1.33B | -1.53B | -1.61B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -91.9M |
| Accumulated OCI | -9.75K | -217.72K | 107.58K | 600K | -4.6M | -19.2M | -3.1M | 1M | 1.2M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARVN Cash Flow Statement
Arvinas, Inc. (ARVN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 5.11M | -16.12M | -40.63M | -89.76M | 559.4M | -273.5M | -347.8M | -259.3M | -273.8M |
| Operating CF Margin % | 67.47% | -112.52% | -94.53% | -346.55% | 1043.66% | -208.14% | -443.06% | -98.44% | -104.27% |
| Operating CF Growth % | 126.35% | -415.22% | -152.06% | -120.93% | 723.24% | -148.89% | -27.17% | 25.45% | -5.59% |
| Net Income | -24.05M | -41.48M | -70.29M | -119.33M | -191M | -282.5M | -367.3M | -198.9M | -80.8M |
| Depreciation & Amortization | 347.39K | 706K | 2.25M | 4.02M | 6M | 8.2M | 6.7M | 6.6M | 5.2M |
| Stock-Based Compensation | 245.05K | 11.63M | 20.07M | 30.2M | 57.1M | 75.5M | 71.6M | 88.2M | 44M |
| Deferred Taxes | -5.87K | 193.78K | 0 | -395.07K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 362.07K | 266.03K | 169.17K | 1.69M | 9M | 7.9M | -14.4M | -14.6M | -8.5M |
| Working Capital Changes | 28.21M | 12.57M | 7.17M | -5.94M | 678.3M | -82.6M | -44.4M | -140.6M | -233.7M |
| Change in Receivables | -25M | 22.22M | 2.78M | -1M | -30.2M | 14M | 800K | -5.7M | 7.3M |
| Change in Inventory | 2.26M | -3.26M | -2.07M | 6.34M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -969.48K | 2M | 1.61M | 2.04M | 27.9M | 20.2M | 17.3M | -21.2M | -1.7M |
| Cash from Investing | 20.87M | -179.67M | -93.1M | 164.25M | -1.31B | 242.8M | 203.5M | 34.7M | 407.6M |
| Capital Expenditures | -1.01M | -2.83M | -6.24M | -6.45M | -4.7M | -6.8M | -2.9M | -1.8M | -1.9M |
| CapEx % of Revenue | 13.36% | 19.76% | 14.53% | 24.89% | 8.77% | 5.17% | 3.69% | 0.68% | 0.72% |
| Acquisitions | 0 | 0 | 86.8M | -395.07M | 0 | 400K | 0 | 100K | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 21.88M | -176.83M | -86.8M | 395.07M | 0 | -400K | 0 | 0 | 0 |
| Cash from Financing | -161.36K | 168.06M | 139.74M | 504.67M | 278.6M | 4.7M | 374.7M | 7.9M | -91.4M |
| Debt Issued (Net) | -161.36K | 1.83M | -169.61K | 0 | 0 | 0 | 0 | -400K | -200K |
| Equity Issued (Net) | 0 | 169.58M | 139.91M | 525.6M | 264.6M | 4.7M | 374.7M | 8.3M | -91.2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -91.9M |
| Other Financing | 0 | -3.35M | 0 | -20.93M | 14M | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.82M▲ 0% | -27.72M▼ 207.4% | 6.02M▲ 121.7% | 579.16M▲ 9519.0% | -475.6M▼ 182.1% | -26M▲ 94.5% | 230.4M▲ 986.2% | -216.7M▼ 194.1% | 42.4M▲ 119.6% |
| Free Cash Flow | 4.1M▲ 0% | -18.95M▼ 562.1% | -46.87M▼ 147.4% | -96.2M▼ 105.3% | 554.7M▲ 676.6% | -280.3M▼ 150.5% | -350.7M▼ 25.1% | -261.1M▲ 25.5% | -275.7M▼ 5.6% |
| FCF Margin % | 54.11% | -132.28% | -109.06% | -371.45% | 1034.89% | -213.32% | -446.75% | -99.13% | -104.99% |
| FCF Growth % | 120.81% | -562.08% | -147.36% | -105.26% | 676.58% | -150.53% | -25.12% | 25.55% | -5.59% |
| FCF per Share | 0.20 | -0.60 | -1.42 | -2.43 | 11.09 | -5.27 | -6.32 | -3.63 | -4.25 |
| FCF Conversion (FCF/Net Income) | -0.21x | 0.39x | 0.58x | 0.75x | -2.93x | 0.97x | 0.95x | 1.30x | 3.39x |
| Interest Paid | 0 | 0 | 0 | 0 | 100K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 11.1M | 11.1M | 2.3M | 0 |
ARVN Key Ratios
Arvinas, Inc. (ARVN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -59.72% | -198.12% | -60.59% | -38.69% | -27.46% | -26.83% | -41.96% | -59.97% | -32.56% | -16.23% |
| Return on Invested Capital (ROIC) | -63.68% | - | -62.41% | -21.62% | -64.77% | -38.38% | -33.82% | -71.65% | -45.63% | -22.37% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 98.02% |
| Net Margin | -215.18% | -317.32% | -289.59% | -163.56% | -460.62% | -356.34% | -214.99% | -467.9% | -75.51% | -30.77% |
| Debt / Equity | 0.02x | 1.26x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.00x | 0.02x | 0.02x |
| Interest Coverage | -213.20x | -476.57x | -721.15x | -702.07x | -1858.46x | -1884.00x | - | - | - | - |
| FCF Conversion | 1.35x | -0.21x | 0.39x | 0.58x | 0.75x | -2.93x | 0.97x | 0.95x | 1.30x | 3.39x |
| Revenue Growth | - | 13.64% | 89% | 200.03% | -39.73% | 106.95% | 145.15% | -40.26% | 235.54% | -0.3% |
ARVN SEC Filings & Documents
Arvinas, Inc. (ARVN) SEC filings — annual & quarterly reports (10-K, 10-Q)
ARVN Frequently Asked Questions
Arvinas, Inc. (ARVN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Arvinas, Inc. (ARVN) reported $262.6M in revenue for fiscal year 2025. This represents a 3838% increase from $6.7M in 2016.
Arvinas, Inc. (ARVN) saw revenue decline by 0.3% over the past year.
Arvinas, Inc. (ARVN) reported a net loss of $80.8M for fiscal year 2025.
Dividend & Returns
Arvinas, Inc. (ARVN) has a return on equity (ROE) of -16.2%. Negative ROE indicates the company is unprofitable.
Arvinas, Inc. (ARVN) had negative free cash flow of $275.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More ARVN
Arvinas, Inc. (ARVN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates